Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE MONTH OF MARCH 2023

 

COMMISSION FILE NUMBER 001-34041

 

Evotec SE

(Translation of registrant’s name into English)

 

Essener Bogen 7

22419 Hamburg

Germany

Tel: [phone]

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐

 

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐

 

  

On March 28, 2023, Evotec SE (the “Company”) announced that the Company has extended and expanded its strategic neurodegeneration partnership with Bristol Myers Squibb (NYSE:BMY), originally signed in 2016. The ad hoc release is attached hereto as Exhibit 99.1. An accompanying press release is attached hereto as Exhibit 99.2.

 

2

 

SIGNATURE

 

Pursuant to the requirements of s the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Evotec SE
	By:	/s/ Enno Spillner
		Name: Enno Spillner
		Title: Chief Financial Officer
Date: March 28, 2023

 

3

 

EXHIBIT INDEX

 

Exhibit			Description of Exhibit
99.1			Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership
99.2			Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership

 

4